Kirkland Advises Warburg Pincus on $17.3 Billion Global Private Equity Fund
Kirkland & Ellis advised Warburg Pincus on the formation of its largest-ever private equity fund, Warburg Pincus Global Growth 14 (WPGG 14). The $17.3 billion global flagship fund was met with strong investor demand, allowing it to exceed its original target of $16 billion at its launch in 2021.
WPGG 14 will pursue a global set of opportunities for investment in growth companies within the firm’s key industry sectors. Significant investments in WPGG 14 to date include Simtra BioPharma Solutions (formerly Baxter’s BioPharma Solutions business), Ensemble Health, EverBank, Internet Brands, Norstella, Oona Insurance, ParetoHealth, and Watertec India.
WPGG 14 is the successor to Warburg Pincus Global Growth, the firm’s prior vintage global fund, raised at $15 billion in 2018. WPGG 14’s limited partners include existing investors in Warburg Pincus’ current funds as well as new investors to the firm. The group of investors represents a diversified mix of leading public and private pension funds, sovereign investors, insurance companies, endowments, foundations, fund of funds, family offices, and high-net-worth individuals.
Read the transaction press release
The team was led by investment funds partners Andrew Wright and Rob Blaustein. The team included investment funds partners Sean Malone, Kevin Lam and Michael Ramsey; investment funds regulatory partners Norm Champ and Alpa Patel; tax partners Dave Grenker and Meredith Levy; and financial services regulatory partners Lisa Cawley and Prem Mohan.
